or water-soluble organic solvent comprises dissolving the HMG-CoA reductase inhibitor in acetone, and then adding water thereto.

44. (new) The process according to claim 40, wherein said crystallization from an organic solvent having limited miscibility or solubility with water comprises dissolving the HMG-CoA reductase inhibitor in said organic solvent at a concentration of 10 to 35 g/l, and removing one-third to three-fourth of said organic solvent.

45. (new) The process according to claim 40, wherein ethyl acetate is used as the organic solvent having limited miscibility or solubility with water.

46. (new) Use of a process according to claim 40 for the isolation and/or purification of lovastatin.

REMARKS

The foregoing amendment is intended to remove the multiple claims and to place the claims in proper U.S. form. It is believed that the application is in condition for allowance.

Respectfully submitted,

Date: July 19, 2000

Timothy M. Murphy
Registration No. 33,198
Attorney for Applicants

BROMBERG & SUNSTEIN LLP
125 Summer Street
Boston, MA 02110-1618
Tel: 617 443 9292
Fax: 617 443 0004

02260/00001 122855.1